• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Baxter beats The Street with Q1 results

April 26, 2018 By Sarah Faulkner

BaxterShares in Baxter (NYSE:BAX) rose today in pre-market activity after the medical device maker beat expectations on Wall Street with its first-quarter results.

The Deerfield, Ill.-based company posted profits of $389 million, or 71¢ per share, on sales of $2.68 billion for the 3 months ended March 31, for bottom-line growth of 43% on sales growth of 8.2% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 70¢, ahead of consensus on The Street, where analysts were looking for sales of $2.62 billion.

“Baxter is off to a strong start in 2018,” chairman & CEO Joe Almeida said in prepared remarks. “Solid top-line performance coupled with a relentless focus on increasing operational efficiency were key drivers of earnings growth in the quarter.”

The company estimated that manufacturing disruptions caused by Hurricane Maria in Puerto Rico took a $25 million hit to its sales results in Q1. Its Puerto Rico-based facilities are all back to pre-hurricane production levels, Baxter noted, but it continues to import select products from other Baxter facilities.

The company raised its financial outlook for the year based on its Q1 results. Baxter said it expects to post adjusted EPS of $2.85 – $2.93 on sales growth of 7% – 8% for the full year.

BAX shares were trading at $68.25 apiece today in pre-market activity, up 2.5%.

“Investors largely expect BAX to over-deliver on operating leverage, in our view, but this solid U.S. sales growth performance – albeit likely helped to some extent by a busy flu season – could continue to positively surprise investors,” Leerink analysts Danielle Antalffy & Rebecca Wang wrote in a note to investors.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Baxter International

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS